Audentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Results of Operations and Financial Condition

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On August 10, 2017, the Company reported its financial results for the quarter and six months ended June 30, 2017. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.





Press release dated August 10, 2017.

Audentes Therapeutics, Inc. Exhibit
EX-99.1 2 bold-ex991_15.htm EX-99.1 bold-ex991_15.htm   Exhibit 99.1     Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update   – Audentes plans to initiate Phase 1/2 clinical trials for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) and AT342 to treat Crigler-Najjar Syndrome in the third quarter of 2017     – Audentes plans to report preliminary clinical data from Phase 1/2 studies of AT132 and AT342 by the end of 2017   – In April 2017,…
To view the full exhibit click here

About Audentes Therapeutics, Inc. (NASDAQ:BOLD)

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

An ad to help with our costs